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Major depressive disorder (MDD) affects millions of individuals and causes significant suffering worldwide. It has been speculated
that MDD is associated with accelerated aging-related biological and functional decline. To examine the accelerated aging
hypothesis, one of the biomarkers under study is leukocyte telomeres, and specifically themeasure of telomere length and telomerase
activity.This review integrates findings from eleven human studieswhich evaluated telomere length and telomerase activity, in order
to synthesize the state of the current science and to inform the development of new knowledge and enhance nursing research of
depression using appropriate biobehavioral measures. Although preliminary, the findings from this integrated review suggest that
there is evidence to support a conceptualization of depression as a stress-related condition in which telomeres shorten over time
in relation to cumulative exposure to the chronic stress of depression. For the purposes of testing in future nursing research, visual
representations of the theoretical connection between stress vulnerabilities, depression, and health outcomes and key moderators
and mediators involved in this conceptualization are provided. The findings from this review and the conceptual framework
provided may be a useful step towards advancing therapeutic nursing interventions for this debilitating chronic condition.
1. Introduction
Major depressive disorder (MDD) affects millions of individ-
uals and causes significant suffering worldwide. The lifetime
prevalence of MDD is approximately 16.2% [1] with women
experiencing a disproportionately higher burden of MDD
than men [2, 3]. The current DSM-IV-TR diagnostic criteria
for MDD include a depressed mood and/or anhedonia for at
least two weeks, plus additional symptoms such as excessive
worrying, guilt, suicidal ideations, psychomotor changes,
and alterations in sleep, weight, appetite, and cognitions [4].
Up to 50% of depressed individuals experience inadequate
symptom relief from typical pharmacologic treatments [5].
Those with partial or no responses to treatment experience
significant decreases in quality of life and functionality [6].
In addition to prolonged psychological distress, individuals
with major mental illnesses, such as MDD, have shorter
life expectancies and higher rates of other chronic medical
conditions, such as cardiovascular disease, metabolic dis-
orders, and chronic pain conditions [7, 8] compared with
the general population. Thus, it has been speculated that
MDD is associated with accelerated aging-related biological
and functional decline. One of the biomarkers under study
to examine the accelerated aging hypothesis is leukocyte
telomeres and specifically the measure of telomere length
and telomerase activity. This review integrates findings from
human studies using biomarkers of telomere length and
telomerase activity, in order to synthesize the state of the
current science and to inform the development of new
knowledge and enhance nursing research of depression using
appropriate biobehavioral measures.
1.1. Potential Mechanism of MDD: Psychological Stress and
Cellular Aging. Multiple potential mechanisms have been
indicated in the etiology of MDD, many of which highlight
the role of stress in both the development and the poten-
tial outcome of living with MDD. Psychological life stress
and MDD are most often comorbid and there is a cyclic
relationship in neurological mechanisms involved in mood
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and stress responsivity. For example, there is a “kindling”
effect in the chronic nature of depression, such that every
major depressive episode (MDE) increases the likelihood of
recurrence [9]. Stress and depression are clearly linked, as
depression may be a cause and/or outcome of chronic stress
and increased stress levels can significantly affect the duration
and degree of symptoms of depression [10–13]. Stress is
considered to be one of the most significant predictors of
health and MDD is a leading contributor to disease and a
major cause of disability in the United States [14–16]. Stress
and depression are associated with increased morbidity and
mortality [10, 17], and this may be due to the fact that
individuals with MDD have a significantly increased risk
of other chronic medical illnesses, such as cardiovascular
disease, diabetes, osteoporosis, and overall frailty/disability,
[18–20]. This correlation between MDD and aging-related
illnesses suggests that MDD may be related to accelerated
cellular aging [21].
The connection between MDD and accelerated cellu-
lar aging may be via inflammatory pathways, and thus
inflammatory states are of particular interest in depression
research for several reasons. First, inflammation-mediated
“sickness behaviors” (e.g., social withdrawal, anhedonia,
fatigue) are classic symptoms of depression [9, 22]. Second,
inflammation has been linked to telomere shortening and
inflammation is linked to many conditions of aging, such
as cardiovascular disease, endocrine disorders, and dementia
[21, 23]; cytokines, which are proteins involved in intercellular
signaling for the regulation of injury and infection, may be
responsible for this link. Proinflammatory cytokines, such
as IL-6 and TNF-alpha, have been demonstrated to increase
telomerase activity in human multiple myeloma cells and
peripheral blood lymphocytes [24–26]. Other studies have
demonstrated significant reductions in telomerase activity
in relation to the inflammatory milieu of acute stress or
exposure to high levels of cortisol [27–29]. Third, inflamma-
tion causes oxidative stress, which in turn leads to telomere
shortening [30]. For these reasons, the association of MDD
with inflammation is a target of keen research interest.
1.2. Telomere Measures. The measure of TL is a novel
approach for understanding correlations between genetic
or environmental factors and physical and mental health.
As “caps” on the ends of chromosomes, telomeres are
protein complexes which protect the chromosome during
cell division. Telomeres become shorter with every cell
division, eventually limiting the cell’s lifespan. Telomerase
is an enzyme which maintains telomere length by adding
DNA base pairs (bp) to the shortened telomere, thus pro-
moting longevity of the cell [31]. Compelling evidence from
recent research suggests that one mechanism by which stress
adversely affects physical health may be related to decreased
activity of the enzyme telomerase which results in shortened
telomere length (TL) [32–35]. When telomerase activity
(TA) decreases, telomeres shorten faster than normal, which
can lead to loss of cell function or even cell death [36].
Considered to be an indicator of accelerated aging, shortened
TL and decreased TA are associated with adverse health
sequalae, such as increased overall mortality and morbidity
and increased rates of cardiovascular events, cerebrovascular
events, cancer, reduced fertility, pulmonary fibrosis, and
dementia, [35, 37–42]. Affected by dynamic changes in telom-
erase activity, TL may be a novel outcome measure of the
cumulative effects of various cellular stressors, both genetic
and environmental [31]. Changes in telomere lengthmay take
months or years to be detectable in research studies, whereas
changes in telomerase activitymay be seen overmuch shorter
periods [28]. Telomerase activity may be influenced by
nonmodifiable factors, such as age and genetic vulnerabilities,
and modifiable factors including chronic stress, oxidative
stress/inflammation, infections, and elevated cortisol, [27, 31,
36, 42, 43]. It has been theorized that increased TA may
initially occur in immune cells as a compensatory response
for extensive stress-induced shortening of telomeres and that
eventually telomerase activity decreases to subprime levels,
leading to continued accelerated aging [26].
2. Materials and Methods
An integrative review was used to examine human research
studies that focused onMDD and measures of cellular aging,
telomere length, and levels of circulating telomerase. The
search of the electronic databases PubMed/Medline and
CINAHL from their date of inception to October 2012 used
key words “depressive disorder,” “telomere,” “telomerase,”
“telomere shortening,” “telomere homeostasis,” “epigenesis,
genetic.” Hand searches were also completed using references
from previously published studies and literature reviews.
Articles that were retrieved via thesemultiple searchmethods
(𝑛 = 202) were reviewed for duplication and for whether
they met the following inclusion criteria: (1) research study
with human participants; (2) participants met diagnostic
criteria for major depressive disorder (MDD) and/or a major
depressive episode (MDE); (3) the study used quantitative
outcome measures of telomere length (TL) or telomerase
activity (TA); (4) the study reported clear methodologies for
measuring telomere length. Because MDD often presents as
multiple recurrent major depressive episodes (MDEs), we
included studies of participants reportingMDEs. In addition,
many individuals with depressive symptoms do not always
seek care and may not have received an official diagnosis of
MDD or MDE [1]; we also evaluated studies that included
participants self-reporting depressive symptoms. Figure 1
represents the process of literature selection. A total of 11
articles met these inclusion criteria and are included in this
review. Table 1 is provided as a summary of the findings.
3. Results
A summary of findings related to the association of depres-
sion with TL and/or TA may be found in Table 1. Eleven
studies evaluated these measures in participants with MDD
and/or MDEs or self-reported depression. The majority of
the studies are cross-sectional in design, with only one
longitudinal study of participants with MDD. In the ear-
lier studies (2006–2010), the Southern blot method was
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Figure 1: Flow diagram of the literature selection process.
used for measuring telomere length. However, most of the
studies were published since 2011 and used the quantitative
fluorescence in situ hybridization (qFISH) or quantitative
polymerase chain reaction (qPCR) methodologies for mea-
suring telomere length, suggesting that interest in telomere
biology and the state of the science is rapidly progressing.
Potentially complicating our analysis of the review findings,
the types of participants evaluated in the studies are quite
varied; for example, one study evaluated outpatients with
heart disease andMDD [44], another evaluated unmedicated
outpatients with MDD [18], and another evaluated hospital-
ized patients with MDD starting antidepressant medication
[45]. The primary constant among all of the studies was that
participants had either a diagnosis of MDD (8 studies) or a
previous history of MDEs/depressive symptoms (3 studies)
and telomere length was measured (all studies).
3.1. Studies of Participants withMDD. Eight studies evaluated
the association between telomere length andmajor depressive
disorder. All of the studies with the exception of one found
that participants with MDD had significantly or close to sig-
nificantly shortened telomeres compared to controls. Two of
the three studies that measured inflammation found a signif-
icant relationship between proinflammatory markers (CRP,
IL-6) and shortened telomeres in depressed participants. To
provide a chronological perspective of the studies and the
development of the science over time, each study is briefly
reviewed, in chronological order, including a discussion of
key findings and limitations.
Simon and colleagues (2006) [46] evaluated telomere
length in participants with either MDD (𝑛 = 15), bipolar
disorder with comorbid anxiety (𝑛 = 15), or bipolar disorder
without comorbid anxiety (𝑛 = 14), as compared to age-
matched controls (𝑛 = 44). Leukocyte telomere length data
was analyzed using the Southern blot method. There were
no TL differences when comparing the three types of mood
disorders, so the groups were combined for comparison
with age-matched controls. Telomere length was significantly
shorter in thosewithmood disorders compared to the control
group, with an overall mean difference of 660 base pairs (𝑡 =
3.16, 𝑃 = 0.002). This significance remained when adjusting
for age, gender, and a lifetime smoking history. Simon et al.
suggest that this mean difference reflects approximately 10
years of accelerated aging in those with a mood disorder.
Neither age nor smoking status was predictive of telomere
length. One limitation in the reporting of this study is that
it was unclear whether the age-matched controls were closely
evaluated to rule out mood disorders. Like many of the other
studies of this nature, this study was limited by a lack of
ethnic/racial diversity, no BMI data (which is known to affect
TL), and no evaluation of stress levels.
Hartmann and colleagues (2010) [45] conducted an
evaluation of the telomere length of hospitalized patients
with MDD (𝑛 = 54) who were receiving various levels
of treatment: low doses of antidepressants (𝑛 = 20), high
doses of antidepressants (𝑛 = 16), and antidepressants plus
electroconvulsive therapy (𝑛 = 18). Each of these groups
were compared to each other and to healthy age-matched
controls (𝑛 = 20). The mean leukocyte telomere length
(analyzed by Southern blot) of all of the depressed subjects
(7.20 ± 0.61 kb) was significantly shorter than the TL of the
control subjects (7.55±0.54 kb;𝑃 < 0.01); this reflects amean
difference of approximately 350 base pairs. Interestingly,
there was no correlation noted between TL and smoking
status, gender, duration or severity of depression, or number
of hospitalizations. However, consistent with other studies,
all subjects had age-dependent shortening of the telomeres
(approximately 20 base pairs per year) no matter whether
they were healthy or had depression. This data is limited in
that BMI data was not reported, 100% of the subjects were
Caucasian, and there was no evaluation of stress levels.
Similarly, findings from the study by Wolkowitz and
colleagues (2011) [18] suggest that chronicity is a key concept
in the relationship between depression and telomere length.
In this study of unmedicated individuals with MDD (𝑛 =
18) as compared to healthy age, sex, and ethnicity-matched
controls (𝑛 = 17), those who had experienced depression the
longest had significantly shorter telomeres than the control
group (𝐹 = 2.87, 𝑃 = 0.05), which corresponded to
approximately 280 base pairs or 7 years of accelerated aging.
Although there was no overall difference between groups
in terms of telomere length or measures of oxidative stress
and inflammation (IL-6 and F2-isoprostanes and Vitamin
C levels), IL-6 concentrations were inversely correlated with
telomere length in the depressed group (𝐹 = 3.29, 𝑃 < 0.05)
and was approaching significance among all participants
(𝐹 = 2.45, 𝑃 = 0.07). Wolkowitz and colleagues (2012)
[49] continued this line of research in a study of patients
completing an open-label study of sertraline (𝑛 = 16)
compared to healthy matched controls (𝑛 = 18). Baseline
telomerase activity levels were elevated in those with MDD
as compared to the controls (𝑃 = 0.007) and, similarly,
higher baseline telomerase activity was positively correlated
with higher levels of depression and stress (𝑃 < 0.05). Lower
baseline telomerase activity was correlated with improved
depression severity over time. Surprisingly, there were no
significant relationships noted between telomerase activity
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Table 1: Overview of studies: telomere length and depression.
First author,
date
Type of study,
total 𝑛 Method
TL shorter in
participants with
MDD or MDE or
depression symptoms
Mean difference in
TL, approx. years of
accelerated aging
Other findings Studylimitations
Studies of participants with MDD
Simon, 2006
[46]
Cross-section,
𝑛 = 88
LTL-Southern
blot Yes
∗ 660 bps, ∼10 yrs — a, b, c
Lung, 2007
[47]
Cross-section,
𝑛 = 664
LTL-Southern
blot Yes
∗ 96 bps, ∼2 yrs — a, b, c
Hartmann,
2010 [45]
Cross-section,
𝑛 = 74
LTL-Southern
blot Yes
∗ 350 bps, ∼5 yrs — a, b, c
Hoen, 2011
[44]
Cross-section,
𝑛 = 952
PBMCs-qPCR Yes∗∗ 97 bps, ∼2 yrs — c
Wolkowitz,
2011 [18]
Cross-section,
𝑛 = 35
LTL-qPCR Yes∗ 280, ∼7 yrs IL6 inversely correlated with TLin depressed pts∗ b
Malan, 2011
[48]
Cross-section,
𝑛 = 64
LTL-qPCR
BTL not associated
with development of
MDD in 3 months
— TL associated with developmentof PTSD∗∗ b, d
Wolkowitz,
2012 [49]
Longitudinal,
𝑛 = 34
PBMCs
TRAPeze assay
for TA
Yes∗ (reported in
Wolkowitz 2011 [18]) 280, ∼7 yrs
BTA elevated in depression∗ and
high stress∗; lower BTA
predicted better response to
antidepressant∗; no correlation
between TA, IL6, CRP, and TL
—
Wikgren,
2012 [50]
Cross-section,
𝑛 = 542
LTL-qPCR Yes∗ 277 bps, ∼4 yrs
TL shorter and CRP higher in
MDD with low post-DST cortisol
levels∗
a, c
Studies of participants with history of MDEs or self-reported depression symptoms
Elvsashagen,
2011 [51]
Cross-section,
𝑛 = 56
PBMCs-qFISH Yes∗∗ 552 bps, ∼9 yrs — b, c, e
Shaffer, 2012
[52]
Cross-section,
𝑛 = 2225
LTL-qPCR No — — a, b, c, e
Hoen, 2013
[53]
Longitudinal,
𝑛 = 974
LTL-qPCR No — Anxiety disorder associated withshorter TL over time∗∗ e, f
∗Significant: P < 0.05; ∗∗trend: P < 0.10.
LTL: leukocyte telomere length; BTL: baseline telomere length; BTA: baseline telomerase activity; DST: dexamethasone suppression test; qPCR: quantitative
polymerase chain reaction; qFISH: quantitative fluorescence in situ hybridization.
aUnclear if controls actually screened for MDD or controls answered in negative regarding previous diagnosis of MDD.
bFactors potentially affecting TL not evaluated/reported (stress, BMI, smoking status, physical activity, anti-inflammatory medications).
cHomogeneous group or ethnicity/races unreported.
dTesting unidirectional hypothesis (telomere length leads to development of depression).
eNo clinical diagnosis of depression (self-report of previous MDE or depression symptoms).
fBiomarkers measured at different time point than depression diagnosis.
and telomere length, nor were there correlations between
telomerase activity and measures of inflammation (IL-6,
CRP).
Hoen et al. (2011) [44] evaluated a group of older
predominantly male patients with coronary heart disease
and found that those with MDD (𝑛 = 206) had shorter
mean telomere lengths (0.86 ± 0.02 versus 0.90 ± 0.01,
𝑃 = 0.02) than those without depression (𝑛 = 746). This
difference inTL reflects approximately 2.3 years of accelerated
aging in those with depression. The finding became a trend
(𝑃 = 0.06) when controlling for characteristics that differed
between groups (age, gender, BMI, smoking status, physical
inactivity, antidepressant use, anxiety, left ventricular ejection
fraction, and statin use). A five-year follow-up found that,
although depression seemed to initially be correlated with
shorter telomeres, depression status did not predict the
subsequent shorter telomere lengths. However, this finding
is complicated by the fact that the researchers did not
evaluate depressive symptoms or diagnoses at followup, so it
is unknown whether this lack of correlation is meaningful.
Lung and colleagues (2007) [47] evaluated 253 outpa-
tients with MDD, compared to healthy controls (𝑛 = 411) for
differences in telomere length. The most significant finding
was that the group withMDD had shorter telomeres than the
control group (8.17±0.61 and 9.13±1.49, resp., 𝑡 = 11.64,𝑃 <
0.01), although potential confounders were not measured
(life stress, BMI, smoking, physical activity, and others).
Similarly, Wikgren and colleagues (2012) [50] found that
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outpatients with recurrent MDD (𝑛 = 91) had significantly
shorter leukocyte TL than healthy controls (𝑛 = 451),
adjusting for age and gender (𝑃 = 0.001; approximately 277
base pair difference). Interestingly, telomere length was not
correlated with smoking status, BMI, or C-reactive protein
levels in either group. Testing the hypothesis that long-
term chronic stress leads to a hypoactive HPA axis and
that depression is a state of chronic stress, Wikgren et al.
assessed participants’ stress with the objective measure of
a low-dose dexamethasone suppression test (DST). Of the
participants with MDD, those with low post-DST cortisol
levels had shorter TL (𝑃 = 0.007, difference of 332 base pairs),
suggesting that TL differences between MDD and healthy
participants may be related to hypocortisolemia.
The only study that did not find a correlation between
depression and telomere length was the study by Malan
et al. (2011) [48] which evaluated the relationship between
the development of MDD and leukocyte telomere length
in women who were survivors of rape, hypothesizing that
those with shorter TL would be more susceptible to the
development of MDD or PTSD. Of the 64 women in the
study, 36% (𝑛 = 23) had MDD at baseline and 41% (𝑛 =
31) had MDD at a 3-month follow-up appointment. There
was no association between relative TL and the development
of MDD and there was a nominally significant association
between TL and PTSD. This study may be limited in that it
evaluated a very specific population who had just recently
experienced a traumatic event to test a unidirectional hypoth-
esis that a shorter telomere length leads to depression. It
has been suggested in the literature that the relationship
between a mood disorder and telomere length is most
likely bidirectional, in that a stressful depressive episode
may actually lead to telomere changes and not vice versa
[21]. Furthermore, depressive symptoms may not show up
immediately in individuals recently experiencing a trauma.
3.2. Studies of Participants with Self-Reported MDEs or
Depression Symptoms. In order to understand whether self-
reported depressive symptoms alone (without a clinical
diagnosis of depression) are related to differences in telomere
length, we have included studies that involved participants
who provided self-reports of either previous depressive
episodes or depressive symptoms. Of the three studies of this
kind, one found a significant correlation between depressive
episodes and telomere length. Elvsashagen and colleagues
(2011) [51] evaluated the correlation between lifetime depres-
sive episodes and PBMC telomere length (measured with
quantitative fluorescence in situ hybridization qFISH) in
individuals with bipolar-II disorder (𝑛 = 28) as compared
with healthy age, gender, and education-matched controls
(𝑛 = 28); there was a positive correlation between the
number of depressive episodes and the percentage of short
telomeres (𝑟 = −0.35, 𝑃 = 0.02) and a trend such that
as the lifetime number of depressive episodes increased, the
mean telomere length decreased by an average of 552 bps
(𝑟 = −0.35, 𝑃 = 0.08). This is an interesting finding
which suggests that chronicity may be a key factor in the
relationship between mood disorders and telomere length.
Consistent with the concept of “kindling” (one episode of
depression increases the likelihood of another), it appears
that increased numbers of depressive episodes may enhance
the shortening of telomeres. These findings are in line with
the literature which suggests that accelerated aging occurs
due to the physiologic and psychological stress induced by
depressive episodes.
Two studies evaluated participants with self-reported
depression symptoms only (no diagnosis of MDD or aMDE)
and neither found statistically significant results. Shaffer et al.
(2012) [52] sampled apparently healthy homogeneous Nova
Scotians (𝑛 = 2225) and found that those with depressive
symptoms did not have significantly shorter TL than those
without, when adjusting for age and sex. It is important
to note that, in this study, there was no clinical diagnosis
of depression whereas the other studies reviewed here had
some method of clinician-based assessments of a depressive
disorder. Hoen et al. (2013) [53] conducted a sample of
subjects inTheNetherlands (𝑛 = 974) in which 9% had either
MDD or dysthymia. This study found that the presence of a
depressive disorder did not predict shorter telomere length at
a two-year followup (𝑃 = 0.753). As with the Shaffer study,
a limitation of this study was that the depression instrument
was self-administered and not clinically confirmed. Another
significant limitation of this study was that psychopathology
and telomere length were measured at time points separated
by multiple years and there was no repeated measure of
psychopathology.
4. Discussion
The findings from this integrated review suggest that there
is preliminary evidence to support a conceptualization of
depression as a stress-related condition in which telomeres
shorten over time in relation to cumulative exposure to the
chronic stress of depression. The majority (8 of 11) of the
studies reviewed herein found that individuals with MDD
or those with a history of MDEs/depressive symptoms have
significantly or close to significantly shortened telomeres
compared to controls, reflecting an “accelerated aging” of
approximately 2–10 years. In addition, preliminary findings
suggest a relationship between depression,markers of inflam-
mation (such as IL-6 and CRP), and telomere length. Finally,
although telomerase is known to be involved in telomere
maintenance, telomerase activity was only measured in one
study so the significance of the findings with regards to
depression is unclear.
The findings from this review are limited for a number
of reasons. First, there have been relatively few studies
focusing on major depression independent of other major
chronic illnesses and there was a variety of definitions of
depression used. Second, the majority of these are cross-
sectional which limits the ability to determine a cause-
effect relationship. Third, these studies have used a variety of
measures so it is difficult to directly compare results. Fourth
and finally, as reflected in Table 1, many of these studies
have numerous limitations such as unclear reporting about
screening/diagnosis of MDD, a lack of control for potentially
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Figure 2: Accelerated cellular aging: stress vulnerability, depression, and health outcomes. SES = socioeconomic status; ECD = early
childhood development; HPAA = hypothalamus-pituitary-adrenal axis; TA = telomerase activity; TL = telomere length; MDD = major
depressive disorder; MDEs = major depressive episodes; QoL = quality of life.
confounding variables (e.g., stress, BMI, smoking, physical
activity, anti-inflammatory medication use), homogenous
samples or unclear reporting of ethnicities/races of samples,
testing unidirectional hypotheses, lack of a clinical diagnosis
of depression, and mismatched assessment time points of
biomarkers and depression.
Despite these limitations, the clinical implications of
telomere shortening in depression warrant attention and
future long-term studies. Although cross-sectional studies
limit the ability to determine causality and very few longitu-
dinal studies have been published at the time of this writing,
telomere length may be a clinically important objective
outcomemeasure for longitudinal intervention studies [21, 31,
33]. Individuals with stress and depression may have accel-
erated telomere shortening which has been seen in previous
nonexperimental research on individuals with psychological
stress and mood disorders. A cross-sectional study of healthy
women by Epel and colleagues (2004) [29] revealed that the
perception of high levels of stress and the chronic nature
of stress is correlated with shortened TL. Evidence from
a number of other epidemiologic studies suggests that in
cases of chronic stress and/or clinical psychological disorders,
telomerase activity decreases, thus resulting in shortened
telomeres by anywhere from 240 to 1750 bp [32, 36, 46].
While objective measures of stress and clinically diagnosed
mood disorders show correlations with shortened TL, sub-
jective cognitive perceptions of life stress also appear to be
significantly correlated with TL. High scores on the Perceived
Stress Scale (PSS) were correlated with shortened TL in
premenopausal women [34, 36]. Furthermore, participants’
self-rating of depression level has been inversely correlated
with TL, such that high levels of depression are seen in
individuals with shorter TL [43].
Future research is warranted to determine the implica-
tions of changes in TL and TA over time.The combination of
measuring TA and TLmay be relevant for use in longitudinal
studies because changes in TA may be seen within a few
days, whereas TL may take months or years to change [54].
However, an inconsistent relationship betweenTAandTLhas
been demonstrated in studies of chronic stress. Findings from
some studies suggest that TA is compensatorily induced by
stress and telomere shortening whereas others suggest that
TA is decreased in chronic stress or depression and thus TL
is shortened (see [21, 54]). Future research should continue
to account for the fact that TA and TL may be influenced by
nonmodifiable factors (e.g., age, race/ethnicity, and gender)
and, modifiable factors (e.g., stress, inflammation, infections,
elevated cortisol, BMI, and physical activity) [21]. Age, race,
and BMI are often used as covariates in studies which have
evaluated stress levels and mental health [34–36, 47, 55];
Nursing Research and Practice 7
Chronic stress in depression
↓ Potentially protective mediators 
◼ Counterregulatory neurosteroids (DHEA, 
allopregnanolone)
◼ Inhibitory neurotransmitters (GABA) 
◼ Insulin sensitivity
◼ Antioxidants (Vit C, E) 
◼ Neurotrophic factors (BDNF)
◼ Anti-inflammatory/immunoregulatory
cytokines (IL-10)
HPAA dysfunction and neurobiological 
alterations
Potential moderators: 
genetic and epigenetic factors, 
cognitive appraisal, social 
support, coping styles, and so on 
Immune 
dysregulation
Accelerated cellular aging
↑↓  TA
↑ TL
↑ Potentially damaging mediators 
◼ Hyper/hypocortisolemia (and ↓ 
glucocorticoid receptors) 
◼ Synaptic glutamate
◼ Intracytoplasmic calcium
◼ Free radicals
◼ Proinflammatory cytokines (IL-6,
Inflammation and 
oxidative stress
TNF-𝛼)
Figure 3: Highly simplified schema of mediators andmoderators potentially related to cell damage or dysfunction, accelerated cellular aging,
and depression.
however, the majority of the studies in this review did not
do so. Research suggests that TL is inversely related to BMI
and age [42, 56] and African Americans have longer TL than
Caucasians [42]. There is a small dose effect of age on TL
by decade before age 50 [31], where average TL shortening
during adulthood may be 30–60 bp per year [29, 33]. It is
unclear, however, whether TL should be used as a marker of
illness vulnerability versus actual ongoing disease or rather as
a reflection of the sequelae of stress involved in depression.
Considering the extant literature supporting the connec-
tion between psychosocial stress, depression, and telomere
length (see reviews such as [21, 54, 57]), it is clear that there are
interrelated pathways involved in stress and depression. Fig-
ure 2 provides a visual representation of theoretical connec-
tions between stress vulnerabilities, depression, and health
outcomes, in which the physiological changes occurring in
depression may be reflected in biomarkers of accelerated
cellular aging [9, 21, 54, 57]. For example, stress hormones and
inflammationmay be important mediators between telomere
length, depression, and stress; a recent study found that high
levels of pessimism, typical in depression, may be correlated
with shortened leukocyte telomere length and elevated levels
of IL-6 [58]. Figure 3 provides an oversimplified schema of
potential moderators and mediators involved in accelerated
cellular aging (for more details, see [59]). These models
do not depict the complex relationships between many of
these mediators but rather provide preliminary theoretical
models for testing in future research. For instance, although
shortened telomere length may reflect an accumulation of
stress with chronic depression, it may be too early to con-
fidently assert that TL may be used as a reliable biomarker
in depression and research is needed to determine whether
telomeric aging is reversible [60].Thesemodelsmay be tested
and applied in order to enhance our understanding of under-
lying mechanisms of interventions for depression and stress;
for example, recent studies suggest that mindfulness, yoga,
and relaxation techniques may be therapeutic interventions
for mitigating the effects of chronic stress and depression,
possibly preventing stress-related accelerated cellular aging
[33, 55, 61–63].
5. Conclusion
In conclusion, we have conducted an integrated review of
eleven research studies which evaluated the association of
depression with telomere length. The findings suggest that
there is preliminary evidence to support the conceptualiza-
tion of depression as a state of stress-induced accelerated
cellular aging, as represented by shortened telomeres. Despite
themultiple limitations of the various studies and considering
that it is still unclear how well telomere length may serve as
a biomarker in depression, the findings are consistent with
the literature which suggests telomere pathology is relevant
in other chronic illnesses and chronic stress. It has been
suggested that telomere shortening may be the “missing link”
for understanding morbidity and mortality in depression
8 Nursing Research and Practice
[57]. Although the state of the science may still be relatively
new in this field, TL appears to be an important novel
outcome measure to incorporate into longitudinal studies.
For the purposes of testing in future research, we have
presented a visual representation of the theoretical connec-
tion between stress vulnerabilities, depression, and health
outcomes (Figure 2) as well as a simplified schema of key
moderators and mediators involved in this conceptualization
(Figure 3). Nursing research has historically been highly
involved in investigating underlying mechanisms of and
interventions for depression. The provocative findings from
this review provide insights into the possible relationships
between depression, chronic stress, and cellular aging and
this may be a useful step towards advancing therapeutic
nursing interventions for this debilitating chronic condition.
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